Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Identifieur interne : 001495 ( Main/Exploration ); précédent : 001494; suivant : 001496Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Auteurs : Mark C. Gillies [Australie] ; Vuong Nguyen [Australie] ; Vincent Daien [France] ; Jennifer J. Arnold [Australie] ; Nigel Morlet [Australie] ; Daniel Barthelmes [Suisse]Source :
- Ophthalmology [ 1549-4713 ] ; 2016.
Descripteurs français
- KwdFr :
- Acuité visuelle (physiologie), Angiographie fluorescéinique, Dégénérescence maculaire humide (diagnostic), Dégénérescence maculaire humide (physiopathologie), Dégénérescence maculaire humide (traitement médicamenteux), Enregistrements, Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs), Femelle, Humains, Inhibiteurs de l'angiogenèse (administration et posologie), Inhibiteurs de l'angiogenèse (usage thérapeutique), Injections intravitréennes, Mâle, Protéines de fusion recombinantes (administration et posologie), Protéines de fusion recombinantes (usage thérapeutique), Ranibizumab (administration et posologie), Ranibizumab (usage thérapeutique), Récepteurs aux facteurs de croissance endothéliale vasculaire (administration et posologie), Récepteurs aux facteurs de croissance endothéliale vasculaire (usage thérapeutique), Résultat thérapeutique, Substitution de médicament, Sujet âgé, Sujet âgé de 80 ans ou plus, Tomographie par cohérence optique.
- MESH :
- administration et posologie : Inhibiteurs de l'angiogenèse, Protéines de fusion recombinantes, Ranibizumab, Récepteurs aux facteurs de croissance endothéliale vasculaire.
- antagonistes et inhibiteurs : Facteur de croissance endothéliale vasculaire de type A.
- diagnostic : Dégénérescence maculaire humide.
- physiologie : Acuité visuelle.
- physiopathologie : Dégénérescence maculaire humide.
- traitement médicamenteux : Dégénérescence maculaire humide.
- usage thérapeutique : Inhibiteurs de l'angiogenèse, Protéines de fusion recombinantes, Ranibizumab, Récepteurs aux facteurs de croissance endothéliale vasculaire.
- Angiographie fluorescéinique, Enregistrements, Femelle, Humains, Injections intravitréennes, Mâle, Résultat thérapeutique, Substitution de médicament, Sujet âgé, Sujet âgé de 80 ans ou plus, Tomographie par cohérence optique.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Angiogenesis Inhibitors (administration & dosage), Angiogenesis Inhibitors (therapeutic use), Drug Substitution, Female, Fluorescein Angiography, Humans, Intravitreal Injections, Male, Ranibizumab (administration & dosage), Ranibizumab (therapeutic use), Receptors, Vascular Endothelial Growth Factor (administration & dosage), Receptors, Vascular Endothelial Growth Factor (therapeutic use), Recombinant Fusion Proteins (administration & dosage), Recombinant Fusion Proteins (therapeutic use), Registries, Tomography, Optical Coherence, Treatment Outcome, Vascular Endothelial Growth Factor A (antagonists & inhibitors), Visual Acuity (physiology), Wet Macular Degeneration (diagnosis), Wet Macular Degeneration (drug therapy), Wet Macular Degeneration (physiopathology).
- MESH :
- chemical , administration & dosage : Angiogenesis Inhibitors, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- chemical , antagonists & inhibitors : Vascular Endothelial Growth Factor A.
- chemical , therapeutic use : Angiogenesis Inhibitors, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- diagnosis : Wet Macular Degeneration.
- drug therapy : Wet Macular Degeneration.
- physiology : Visual Acuity.
- physiopathology : Wet Macular Degeneration.
- Aged, Aged, 80 and over, Drug Substitution, Female, Fluorescein Angiography, Humans, Intravitreal Injections, Male, Registries, Tomography, Optical Coherence, Treatment Outcome.
Abstract
To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice.
DOI: 10.1016/j.ophtha.2016.08.016
PubMed: 27707549
Affiliations:
- Australie, France, Suisse
- Languedoc-Roussillon, Nouvelle-Galles du Sud, Occitanie (région administrative)
- Montpellier, Sydney
- Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001532
- to stream PubMed, to step Curation: 001510
- to stream PubMed, to step Checkpoint: 001510
- to stream Ncbi, to step Merge: 003C59
- to stream Ncbi, to step Curation: 003C59
- to stream Ncbi, to step Checkpoint: 003C59
- to stream Main, to step Merge: 001490
- to stream Main, to step Curation: 001495
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.</title><author><name sortKey="Gillies, Mark C" sort="Gillies, Mark C" uniqKey="Gillies M" first="Mark C" last="Gillies">Mark C. Gillies</name><affiliation wicri:level="4"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Nguyen, Vuong" sort="Nguyen, Vuong" uniqKey="Nguyen V" first="Vuong" last="Nguyen">Vuong Nguyen</name><affiliation wicri:level="4"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Daien, Vincent" sort="Daien, Vincent" uniqKey="Daien V" first="Vincent" last="Daien">Vincent Daien</name><affiliation wicri:level="4"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Arnold, Jennifer J" sort="Arnold, Jennifer J" uniqKey="Arnold J" first="Jennifer J" last="Arnold">Jennifer J. Arnold</name><affiliation wicri:level="1"><nlm:affiliation>Marsden Eye Specialists, Parramatta, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Marsden Eye Specialists, Parramatta</wicri:regionArea><wicri:noRegion>Parramatta</wicri:noRegion></affiliation></author><author><name sortKey="Morlet, Nigel" sort="Morlet, Nigel" uniqKey="Morlet N" first="Nigel" last="Morlet">Nigel Morlet</name><affiliation wicri:level="1"><nlm:affiliation>Department of Population Health, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Population Health, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Barthelmes, Daniel" sort="Barthelmes, Daniel" uniqKey="Barthelmes D" first="Daniel" last="Barthelmes">Daniel Barthelmes</name><affiliation wicri:level="4"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27707549</idno><idno type="pmid">27707549</idno><idno type="doi">10.1016/j.ophtha.2016.08.016</idno><idno type="wicri:Area/PubMed/Corpus">001532</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001532</idno><idno type="wicri:Area/PubMed/Curation">001510</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001510</idno><idno type="wicri:Area/PubMed/Checkpoint">001510</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001510</idno><idno type="wicri:Area/Ncbi/Merge">003C59</idno><idno type="wicri:Area/Ncbi/Curation">003C59</idno><idno type="wicri:Area/Ncbi/Checkpoint">003C59</idno><idno type="wicri:Area/Main/Merge">001490</idno><idno type="wicri:Area/Main/Curation">001495</idno><idno type="wicri:Area/Main/Exploration">001495</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.</title><author><name sortKey="Gillies, Mark C" sort="Gillies, Mark C" uniqKey="Gillies M" first="Mark C" last="Gillies">Mark C. Gillies</name><affiliation wicri:level="4"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Nguyen, Vuong" sort="Nguyen, Vuong" uniqKey="Nguyen V" first="Vuong" last="Nguyen">Vuong Nguyen</name><affiliation wicri:level="4"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Daien, Vincent" sort="Daien, Vincent" uniqKey="Daien V" first="Vincent" last="Daien">Vincent Daien</name><affiliation wicri:level="4"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier, France. Electronic address: vincent.daien@sydney.edu.au.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France; Inserm, U1061, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Arnold, Jennifer J" sort="Arnold, Jennifer J" uniqKey="Arnold J" first="Jennifer J" last="Arnold">Jennifer J. Arnold</name><affiliation wicri:level="1"><nlm:affiliation>Marsden Eye Specialists, Parramatta, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Marsden Eye Specialists, Parramatta</wicri:regionArea><wicri:noRegion>Parramatta</wicri:noRegion></affiliation></author><author><name sortKey="Morlet, Nigel" sort="Morlet, Nigel" uniqKey="Morlet N" first="Nigel" last="Morlet">Nigel Morlet</name><affiliation wicri:level="1"><nlm:affiliation>Department of Population Health, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Population Health, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Barthelmes, Daniel" sort="Barthelmes, Daniel" uniqKey="Barthelmes D" first="Daniel" last="Barthelmes">Daniel Barthelmes</name><affiliation wicri:level="4"><nlm:affiliation>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia; Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></analytic><series><title level="j">Ophthalmology</title><idno type="eISSN">1549-4713</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Angiogenesis Inhibitors (administration & dosage)</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Drug Substitution</term><term>Female</term><term>Fluorescein Angiography</term><term>Humans</term><term>Intravitreal Injections</term><term>Male</term><term>Ranibizumab (administration & dosage)</term><term>Ranibizumab (therapeutic use)</term><term>Receptors, Vascular Endothelial Growth Factor (administration & dosage)</term><term>Receptors, Vascular Endothelial Growth Factor (therapeutic use)</term><term>Recombinant Fusion Proteins (administration & dosage)</term><term>Recombinant Fusion Proteins (therapeutic use)</term><term>Registries</term><term>Tomography, Optical Coherence</term><term>Treatment Outcome</term><term>Vascular Endothelial Growth Factor A (antagonists & inhibitors)</term><term>Visual Acuity (physiology)</term><term>Wet Macular Degeneration (diagnosis)</term><term>Wet Macular Degeneration (drug therapy)</term><term>Wet Macular Degeneration (physiopathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acuité visuelle (physiologie)</term><term>Angiographie fluorescéinique</term><term>Dégénérescence maculaire humide (diagnostic)</term><term>Dégénérescence maculaire humide (physiopathologie)</term><term>Dégénérescence maculaire humide (traitement médicamenteux)</term><term>Enregistrements</term><term>Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de l'angiogenèse (administration et posologie)</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Injections intravitréennes</term><term>Mâle</term><term>Protéines de fusion recombinantes (administration et posologie)</term><term>Protéines de fusion recombinantes (usage thérapeutique)</term><term>Ranibizumab (administration et posologie)</term><term>Ranibizumab (usage thérapeutique)</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire (administration et posologie)</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Substitution de médicament</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tomographie par cohérence optique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Ranibizumab</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Ranibizumab</term><term>Receptors, Vascular Endothelial Growth Factor</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de l'angiogenèse</term><term>Protéines de fusion recombinantes</term><term>Ranibizumab</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type A</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Wet Macular Degeneration</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Dégénérescence maculaire humide</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Wet Macular Degeneration</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Acuité visuelle</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Visual Acuity</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Dégénérescence maculaire humide</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Wet Macular Degeneration</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dégénérescence maculaire humide</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de l'angiogenèse</term><term>Protéines de fusion recombinantes</term><term>Ranibizumab</term><term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Drug Substitution</term><term>Female</term><term>Fluorescein Angiography</term><term>Humans</term><term>Intravitreal Injections</term><term>Male</term><term>Registries</term><term>Tomography, Optical Coherence</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Angiographie fluorescéinique</term><term>Enregistrements</term><term>Femelle</term><term>Humains</term><term>Injections intravitréennes</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Substitution de médicament</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tomographie par cohérence optique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Suisse</li></country><region><li>Languedoc-Roussillon</li><li>Nouvelle-Galles du Sud</li><li>Occitanie (région administrative)</li></region><settlement><li>Montpellier</li><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Gillies, Mark C" sort="Gillies, Mark C" uniqKey="Gillies M" first="Mark C" last="Gillies">Mark C. Gillies</name></region><name sortKey="Arnold, Jennifer J" sort="Arnold, Jennifer J" uniqKey="Arnold J" first="Jennifer J" last="Arnold">Jennifer J. Arnold</name><name sortKey="Morlet, Nigel" sort="Morlet, Nigel" uniqKey="Morlet N" first="Nigel" last="Morlet">Nigel Morlet</name><name sortKey="Nguyen, Vuong" sort="Nguyen, Vuong" uniqKey="Nguyen V" first="Vuong" last="Nguyen">Vuong Nguyen</name></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Daien, Vincent" sort="Daien, Vincent" uniqKey="Daien V" first="Vincent" last="Daien">Vincent Daien</name></region></country><country name="Suisse"><region name="Nouvelle-Galles du Sud"><name sortKey="Barthelmes, Daniel" sort="Barthelmes, Daniel" uniqKey="Barthelmes D" first="Daniel" last="Barthelmes">Daniel Barthelmes</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001495 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001495 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27707549
|texte= Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27707549" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |